| Literature DB >> 20717112 |
A Pokhrel1, P Martikainen, E Pukkala, M Rautalahti, K Seppä, T Hakulinen.
Abstract
BACKGROUND: Relative survival after cancer in Finland is at the highest level observed in Europe and has, in general, been on a steady increase. The aim of this study is to assess whether the high survival is equally shared by different population subgroups and to estimate the possible gains that might be achieved if equity prevailed. MATERIALS ANDEntities:
Mesh:
Year: 2010 PMID: 20717112 PMCID: PMC2965870 DOI: 10.1038/sj.bjc.6605861
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Age-standardised 5-year cancer-specific survival proportions for the cancer patients diagnosed in Finland in 1996–2005 by site, sex and educational level (high, secondary, basic) and differences (in % units) between the high and basic categories, by site and period. Patients' site-specific age distributions in 1971–2005 have been used as site-specific standards (both genders combined)
|
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
| Lip | C00 | 98.5 | 98.3 | 97.0 | 1.5 | 96.4 | 99.2 | 97.9 | −1.5 | 4212 |
| Oesophagus | C15 | 19.9 | NA | 9.5 | 10.4 | NA | NA | NA | NA | 5687 |
| Stomach | C16 | 28.8 | 25.2 | 24.0 | 4.7 | 29.2 | 30.0 | 29.9 | −0.7 | 26 958 |
| Colon | C18 | 54.8 | 57.9 | 54.5 | 0.3 | 60.1 | 61.1 | 55.8 | 4.3 | 28 759 |
| Rectum | C19–20 | 59.8 | 55.7 | 52.7 | 7.1 | 62.4 | 57.1 | 56.8 | 5.6 | 19 448 |
| Liver | C22 | NA | NA | NA | NA | NA | NA | 7.5 | NA | 6445 |
| Gallbladder | C23–24 | NA | 15.9 | NA | NA | 9.4 | 8.8 | NA | NA | 6693 |
| Pancreas | C25 | NA | NA | NA | NA | NA | 3.6 | 2.6 | NA | 19 328 |
| Nose | C30–31 | NA | NA | NA | NA | 62.8 | 64.2 | 57.9 | 4.8 | 960 |
| Lung | C33–34 | 10.6 | 9.5 | 9.2 | 1.3 | 18.8 | 13.5 | 12.3 | 6.5 | 66 014 |
| Skin, melanoma | C43 | 82.7 | 78.2 | 77.4 | 5.3 | 91.9 | 88.6 | 84.5 | 7.4 | 14 750 |
| Skin, non-melanoma | C44 | 98.0 | 94.6 | 95.8 | 2.1 | 97.6 | 98.8 | 95.5 | 2.1 | 15 383 |
| Soft tissue | C48–49 | 67.4 | NA | 47.1 | 20.3 | 62.6 | 60.2 | 60.7 | 1.9 | 3468 |
| Breast | C50 | — | — | — | — | 89.4 | 87.1 | 84.9 | 4.5 | 78 292 |
| Cervix uteri | C53 | — | — | — | — | 78.5 | 69.0 | 63.3 | 15.1 | 5563 |
| Corpus uteri | C54 | — | — | — | — | 87.8 | 83.7 | 82.2 | 5.6 | 17 270 |
| Ovary | C56 | — | — | — | — | 53.2 | 47.0 | 44.5 | 8.6 | 12 948 |
| Prostate | C61 | 87.4 | 84.1 | 80.3 | 7.0 | — | — | — | — | 59 308 |
| Testis | C62 | 93.4 | 95.8 | 91.4 | 2.0 | — | — | — | — | 1727 |
| Kidney | C64–65 | 61.1 | 58.9 | 55.2 | 5.9 | 62.1 | 63.6 | 60.8 | 1.3 | 18 117 |
| Urinary bladder | C67–68 | 80.7 | 78.2 | 76.8 | 3.9 | 83.3 | 77.8 | 69.7 | 13.5 | 18 037 |
| Thyroid | C73 | 84.2 | 85.9 | 82.6 | 1.5 | 93.9 | 92.6 | 91.1 | 2.8 | 8066 |
| Hodgkin's lymphoma | C81 | 86.8 | NA | 83.4 | 3.3 | 86.2 | 86.3 | 82.5 | 3.7 | 3099 |
| Non-Hodgkin's lymphoma | C82–85, C96 | 59.8 | 52.4 | 51.1 | 8.7 | 65.8 | 59.4 | 56.6 | 9.2 | 18 818 |
| Multiple myeloma | C90 | 40.5 | 36.3 | 25.4 | 15.1 | 37.4 | 29.5 | 29.3 | 8.1 | 7023 |
| Leukaemia | C91–95 | 49.3 | 47.9 | 40.1 | 9.1 | 45.2 | 38.8 | 39.1 | 6.0 | 11 865 |
| Other cancers | 39.2 | 40.0 | 33.3 | 5.8 | 44.5 | 39.6 | 34.7 | 9.8 | 47 905 | |
| Total | 526 143 | |||||||||
Abbreviation: NA=not estimable; sec=secondary; ICD=international classification of diseases; Diff=differences. Total numbers of cancer patients in 1971–2005 by site are also given.
Figure 1Risk ratios for cancer death of patients diagnosed in 1971–2005 (high vs basic education) without and with accounting for stage, by site (sites: OE=oesophagus; ST=stomach; CO=colon; RE=rectum; LI=liver; GB=gallbladder; PA=pancreas; LU=lung; ME=skin, melanoma; NM=skin, non-melanoma; BR=breast; CE=cervix uteri; CU=corpus uteri; OV=ovary; PR=prostate; KI=kidney; UB=urinary bladder; TH=thyroid; HL=Hodgkin's lymphoma; NHL=non-Hodgkin's lymphoma; OTH=other cancers as specified in Table 1). The model accounts for gender where applicable. The diagonal indicates equality of the two RRs. Results are shown for sites with model convergence only.
Figure 2Risk ratios for cancer death high vs basic education and health-conscious occupational group vs basic education and for patients diagnosed in 1996–2005, by site (sites: ST=stomach; CO=colon; RE=rectum; PA=pancreas; LU=lung; ME=skin, melanoma; NM=skin, non-melanoma; BR=breast; CE=cervix uteri; CU=corpus uteri; OV=ovary; PR=prostate; KI=kidney; TH=thyroid; NHL=non-Hodgkin's lymphoma; LE=leukaemia; OTH=other cancers as specified in Table 1). The model accounts for gender where applicable. Persons in the health-conscious occupational group have been removed from the education categories. The diagonal indicates equality of the two RRs.
Number (N) and proportion (%) of potentially avoidable cancer deaths in Finland by period, age and site in a hypothetical situation where all patients would have the same cancer-specific mortality as those with a high education
|
|
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
| Stomach | 64 | 1 | 87 | 2 | −5 | 0 | 19 | 1 | −8 | −1 | −30 | −2 |
| Colon and rectum | 162 | 5 | 197 | 6 | 324 | 15 | 339 | 14 | 83 | 3 | 35 | 1 |
| Lung | 332 | 3 | 320 | 3 | 24 | 0 | 26 | 0 | 239 | 4 | 214 | 4 |
| Skin, melanoma | 189 | 27 | 228 | 26 | 61 | 12 | 118 | 19 | 143 | 31 | 224 | 36 |
| Skin, non-melanoma | 36 | 59 | 43 | 63 | 21 | 76 | 21 | 61 | 10 | 29 | 15 | 38 |
| Breast | 358 | 10 | 534 | 11 | 530 | 22 | 516 | 14 | 356 | 17 | 387 | 11 |
| Female genital organs | 537 | 20 | 512 | 17 | 208 | 13 | 241 | 13 | 197 | 13 | 216 | 11 |
| Prostate | 96 | 11 | 75 | 7 | 141 | 16 | 136 | 12 | 303 | 27 | 369 | 20 |
| Urinary organs | 390 | 20 | 428 | 19 | 183 | 13 | 220 | 14 | 37 | 3 | −58 | −4 |
| Leukaemia | 62 | 4 | 99 | 6 | 6 | 1 | 46 | 5 | 150 | 23 | 144 | 18 |
| Non-Hodgkin's lymphoma | 102 | 8 | 39 | 3 | 107 | 10 | 115 | 8 | 195 | 18 | 104 | 7 |
| Other sites | 778 | 7 | 618 | 5 | 544 | 7 | 508 | 6 | 481 | 6 | 405 | 4 |
| Total | 3105 | 7 | 3180 | 7 | 2143 | 8 | 2305 | 8 | 2188 | 8 | 2026 | 7 |
| Total excluding. prostate and breast | 2652 | 7 | 2571 | 6 | 1472 | 6 | 1653 | 6 | 1528 | 7 | 1270 | 5 |
|
| ||||||||||||
| Stomach | 121 | 3 | 48 | 1 | 131 | 3 | 112 | 2 | 192 | 5 | 186 | 5 |
| Colon and rectum | 168 | 6 | 243 | 8 | 495 | 9 | 463 | 8 | 504 | 8 | 395 | 6 |
| Lung | 69 | 1 | 66 | 1 | 201 | 2 | 192 | 2 | 180 | 1 | 109 | 1 |
| Skin, melanoma | 36 | 17 | 20 | 8 | 63 | 16 | 72 | 15 | 102 | 17 | 39 | 6 |
| Skin, non-melanoma | −3 | −4 | 3 | 5 | 46 | 33 | 60 | 37 | 93 | 43 | 102 | 45 |
| Breast | 224 | 18 | 253 | 15 | 550 | 28 | 718 | 27 | 616 | 26 | 408 | 12 |
| Female genital organs | 222 | 15 | 214 | 13 | 311 | 12 | 293 | 11 | 599 | 22 | 506 | 17 |
| Prostate | 137 | 8 | 39 | 2 | 541 | 15 | 617 | 13 | 1397 | 31 | 1764 | 25 |
| Urinary organs | 243 | 16 | 241 | 14 | 438 | 16 | 467 | 15 | 490 | 15 | 487 | 13 |
| Leukaemia | 27 | 3 | 67 | 6 | −24 | −2 | −20 | −1 | 23 | 1 | 97 | 5 |
| Non-Hodgkin's lymphoma | 141 | 17 | 176 | 19 | 193 | 9 | 171 | 8 | 466 | 17 | 351 | 12 |
| Other sites | 290 | 3 | 357 | 4 | 785 | 5 | 744 | 5 | 1351 | 7 | 1293 | 6 |
| Total | 1675 | 5 | 1727 | 5 | 3730 | 7 | 3889 | 7 | 6014 | 10 | 5737 | 9 |
| Total excluding prostate and breast | 1314 | 5 | 1435 | 5 | 2638 | 6 | 2554 | 5 | 4001 | 7 | 3565 | 6 |
Number (N) and proportion (%) of potentially avoidable deaths due to cancer and other causes in cancer patients in Finland in 1996–2005, by age, in two hypothetical situations: (A) all patients would have the same cancer-specific mortality and (B) same cancer and competing-risk mortality as those with a high education
|
|
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
| | ||||||||||||
| Total | 2188 | 8 | 2026 | 7 | −167 | −5 | −330 | −5 | 2021 | 7 | 1696 | 5 |
| Total excluding prostate and breast | 1528 | 7 | 1270 | 5 | −148 | −6 | −266 | −6 | 1380 | 5 | 1004 | 3 |
| | ||||||||||||
| Total | 6014 | 10 | 5737 | 9 | −1371 | −6 | −2480 | −7 | 4642 | 6 | 3257 | 3 |
| Total excluding prostate and breast | 4001 | 7 | 3565 | 6 | −1062 | −7 | −1575 | −7 | 2939 | 4 | 1990 | 3 |
|
| ||||||||||||
| | ||||||||||||
| Total | 1984 | 8 | 1703 | 6 | 963 | 27 | 1365 | 22 | 2947 | 10 | 3068 | 8 |
| Total excluding prostate and breast | 1339 | 6 | 986 | 4 | 713 | 28 | 957 | 23 | 2052 | 8 | 1943 | 7 |
| | ||||||||||||
| Total | 5035 | 8 | 4093 | 6 | 4054 | 17 | 3867 | 10 | 9089 | 11 | 7960 | 8 |
| Total excluding prostate and breast | 3191 | 6 | 2478 | 4 | 2186 | 15 | 2054 | 9 | 5377 | 8 | 4532 | 6 |